EP1244445A2 - Use of azoles for preventing skin cancer - Google Patents
Use of azoles for preventing skin cancerInfo
- Publication number
- EP1244445A2 EP1244445A2 EP00983295A EP00983295A EP1244445A2 EP 1244445 A2 EP1244445 A2 EP 1244445A2 EP 00983295 A EP00983295 A EP 00983295A EP 00983295 A EP00983295 A EP 00983295A EP 1244445 A2 EP1244445 A2 EP 1244445A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- azoles
- radiation
- skin cancer
- skin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to the use of azoles for the prevention of skin cancer caused by radiation.
- UN rays are classified into UN-A rays (320-400 nm, UN-AI: 340-400 nm, UN-A-II: 320-340 nm) or UN-B rays (280-320 nm ) assigned.
- UN-A rays 320-400 nm
- UN-AI 340-400 nm
- UN-A-II 320-340 nm
- UN-B rays 280-320 nm
- UN rays can cause acute and chronic skin damage, the type of damage depending on the wavelength of the radiation.
- the UN-B radiation can cause sunburn (erythema) and severe skin burns. Reductions in enzyme activities, disturbances in the D ⁇ S structure and changes in the cell membrane as a damaging effect of the UN-B
- UV-A rays penetrate into the deeper layers of the skin and can accelerate the aging process of the skin there.
- the shorter-wave UV-A-II radiation additionally increases the formation of sunburn.
- UV-A radiation can trigger phototoxic or photoallergic skin reactions.
- the invention makes it possible, for example, to produce azole-containing sunscreens which prevent the UV-induced development of skin cancer, in particular squamous cell carcinoma, basalioma and malignant melanoma. inhibit or prevent entirely.
- the invention thus relates to the use of azoles for the production of topical agents for the prevention of radiation-induced skin cancer.
- Preferred azoles for the prevention of skin cancer correspond for example to the formula
- R represents a trifluoromethyl, methoxy or o-chloro substituent, cf.
- Croconazole l- (l- [2- (3-chlorobenzyloxy) phenyl] vinyl) imidazole
- Clotrimazole l - [(2-chloro-phenyl) -diphenylmethyl] -lH-imidazole
- Fluconazole 2- (2,4-Difluo ⁇ henyl) -l, 3-bis (lH-l, 2,4-triazol-l-yl) -2-propanol
- Isocanazole 1 - [2- (2,4-dichloro-henyl) -2 [(2,6-dichloro-henyl) methoxy] ethyl] -l H-imidiazole
- Itraconazole (+) - 2-sec-butyl-4- [4- (4 - ⁇ [(2R, 4S) -2- (2,4-dichlo ⁇ henyl) -2-
- agents according to the invention can exist in the commonly used forms of application, i.e. e.g. as an oil-in-water or water-in-oil emulsion, as
- Milk as a lotion, cream, aerosol, gel.
- the agents can include commonly used ingredients such as e.g. Emulsifiers, surface-active compounds, lanolin, petroleum jelly, water, triglycerides of fatty acids, polyethylene glycols, fatty alcohols, ethoxylated fatty alcohols, fatty acid esters
- oils and waxes e.g. isopropyl palmate, isooctyl stearate, diisopropyl adipate, etc.
- natural or synthetic oils and waxes e.g. titanium dioxide, zinc oxide, pearlescent pigments, color pigments
- thickeners e.g. hydroxyethyl cellulose, bentonite etc.
- preservatives UV absorbers, moisturizers, Contain silicone oils, vitamins, glycerin, ethyl alcohol, perfume oils.
- the azoles are generally used in amounts of 0.3 to 30, preferably 0.5 to 12, in particular 1 to 6,% by weight, based on the finished preparation (composition).
- the agents according to the invention can be applied to the skin and rubbed in before exposure to radiation. For longer periods of radiation, for example when sunbathing, it is advisable to repeat this process every 2 to 3 hours. After intimate contact with water (bathing, showering), the skin should be completely dried off and rubbed in again with the agent according to the invention if the radiation exposure is to be continued. Effectiveness test
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19963052A DE19963052A1 (en) | 1999-12-24 | 1999-12-24 | Topical composition for preventing radiation-induced skin cancer, e.g. due to sunbathing or radiotherapy, containing azole compound such as bifonazole or clotrimazole |
DE19963052 | 1999-12-24 | ||
PCT/EP2000/012595 WO2001047505A2 (en) | 1999-12-24 | 2000-12-12 | Use of azoles for preventing skin cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1244445A2 true EP1244445A2 (en) | 2002-10-02 |
EP1244445B1 EP1244445B1 (en) | 2005-08-31 |
Family
ID=7934530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00983295A Expired - Lifetime EP1244445B1 (en) | 1999-12-24 | 2000-12-12 | Use of azoles for preventing skin cancer due to radiation |
Country Status (16)
Country | Link |
---|---|
US (1) | US20020193384A1 (en) |
EP (1) | EP1244445B1 (en) |
JP (1) | JP2003518490A (en) |
AR (1) | AR027088A1 (en) |
AT (1) | ATE303146T1 (en) |
AU (1) | AU778835B2 (en) |
BR (1) | BR0017046A (en) |
CA (1) | CA2395345A1 (en) |
CO (1) | CO5251436A1 (en) |
DE (2) | DE19963052A1 (en) |
DK (1) | DK1244445T3 (en) |
ES (1) | ES2246912T3 (en) |
GT (1) | GT200000218A (en) |
MX (1) | MXPA02006247A (en) |
NZ (1) | NZ519731A (en) |
WO (1) | WO2001047505A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2572223C (en) * | 2004-06-25 | 2014-08-12 | The Johns Hopkins University | Angiogenesis inhibitors |
EP1919480B1 (en) * | 2005-08-22 | 2013-01-16 | The Johns Hopkins University | Hedgehog pathway antagonists to treat disease |
EP1895012A1 (en) | 2006-08-30 | 2008-03-05 | Universitätsklinikum Freiburg | Method for inducing tumor apoptosis by increasing nitric oxide levels |
EP2753179A4 (en) | 2011-09-09 | 2015-03-04 | Univ Leland Stanford Junior | Topical itraconazole formulations and uses thereof |
US11185548B2 (en) * | 2016-12-23 | 2021-11-30 | Helmholtz Zentrum Munchen—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases |
CN110917192A (en) * | 2018-09-20 | 2020-03-27 | 华东师范大学 | Application of miconazole in preparation of antitumor drugs |
CN114948947B (en) * | 2021-12-31 | 2023-12-29 | 广州医科大学附属第五医院 | Application of fenticonazole nitrate in preparing antitumor drug |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5633274A (en) * | 1993-02-18 | 1997-05-27 | President And Fellows Of Harvard College | Cancer treatments |
US5998393A (en) * | 1996-04-05 | 1999-12-07 | Kang; Sewon | Methods for assessing 1,25(OH)2 D3 activity in skin and for enhancing the therapeutic use of 1,25(OH)2 D3 |
DE19648010A1 (en) * | 1996-11-20 | 1998-05-28 | Haarmann & Reimer Gmbh | Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation |
US5864393A (en) * | 1997-07-30 | 1999-01-26 | Brown University Research Foundation | Optical method for the determination of stress in thin films |
US6037473A (en) * | 1997-11-13 | 2000-03-14 | Haarmann & Reimer Gmbh | Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation |
MXPA00005036A (en) * | 1997-11-20 | 2003-10-24 | Harvard College | Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation. |
US6108087A (en) * | 1998-02-24 | 2000-08-22 | Kla-Tencor Corporation | Non-contact system for measuring film thickness |
-
1999
- 1999-12-24 DE DE19963052A patent/DE19963052A1/en not_active Withdrawn
-
2000
- 2000-12-12 NZ NZ519731A patent/NZ519731A/en unknown
- 2000-12-12 CA CA002395345A patent/CA2395345A1/en not_active Abandoned
- 2000-12-12 DE DE50011084T patent/DE50011084D1/en not_active Expired - Fee Related
- 2000-12-12 US US10/149,169 patent/US20020193384A1/en not_active Abandoned
- 2000-12-12 JP JP2001548100A patent/JP2003518490A/en active Pending
- 2000-12-12 ES ES00983295T patent/ES2246912T3/en not_active Expired - Lifetime
- 2000-12-12 WO PCT/EP2000/012595 patent/WO2001047505A2/en active IP Right Grant
- 2000-12-12 DK DK00983295T patent/DK1244445T3/en active
- 2000-12-12 EP EP00983295A patent/EP1244445B1/en not_active Expired - Lifetime
- 2000-12-12 AT AT00983295T patent/ATE303146T1/en not_active IP Right Cessation
- 2000-12-12 BR BR0017046-1A patent/BR0017046A/en not_active IP Right Cessation
- 2000-12-12 AU AU20085/01A patent/AU778835B2/en not_active Ceased
- 2000-12-12 MX MXPA02006247A patent/MXPA02006247A/en active IP Right Grant
- 2000-12-20 GT GT200000218A patent/GT200000218A/en unknown
- 2000-12-22 CO CO00097424A patent/CO5251436A1/en not_active Application Discontinuation
- 2000-12-22 AR ARP000106889A patent/AR027088A1/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0147505A2 * |
Also Published As
Publication number | Publication date |
---|---|
AR027088A1 (en) | 2003-03-12 |
GT200000218A (en) | 2002-06-13 |
WO2001047505A2 (en) | 2001-07-05 |
ES2246912T3 (en) | 2006-03-01 |
WO2001047505A3 (en) | 2002-06-20 |
AU778835B2 (en) | 2004-12-23 |
EP1244445B1 (en) | 2005-08-31 |
DE19963052A1 (en) | 2001-06-28 |
AU2008501A (en) | 2001-07-09 |
BR0017046A (en) | 2002-11-05 |
CA2395345A1 (en) | 2001-07-05 |
DK1244445T3 (en) | 2005-11-07 |
MXPA02006247A (en) | 2003-01-28 |
CO5251436A1 (en) | 2003-02-28 |
ATE303146T1 (en) | 2005-09-15 |
DE50011084D1 (en) | 2005-10-06 |
NZ519731A (en) | 2004-06-25 |
US20020193384A1 (en) | 2002-12-19 |
JP2003518490A (en) | 2003-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2416823C (en) | Antimycotic nail varnish composition | |
CH644760A5 (en) | MEANS FOR LOCAL FIGHTING ACNE VULGARIS. | |
CA2706114C (en) | Compositions and methods for treating diseases of the nail | |
IE840463L (en) | Imidazoles and triazoles | |
CA2027876A1 (en) | Use of substituted imidazoles | |
DE10008896A1 (en) | Improving the solubility and compatibility of benzotriazole UV filters in oils, e.g. in cosmetics or dermatological compositions, by addition of dialkylnaphthalates | |
MX2008011435A (en) | External pharmaceutical composition. | |
RU99123064A (en) | NITROGEN COMPOUNDS, THEIR RECEIVING AND APPLICATION | |
EP1244445B1 (en) | Use of azoles for preventing skin cancer due to radiation | |
JP2002521400A5 (en) | ||
US20170290810A1 (en) | Anti-fungal compositions for treating nails and methods for fabricating and using thereof | |
EP0879052B1 (en) | Preparations stimulating nail growth | |
TW496738B (en) | A nail varnish comprising glyceryl triacetate for treatment of onychomycoses | |
SK285763B6 (en) | Water soluble azoles as broad-spectrum antifungals, processes for preparation, use as a medicine | |
DE2635665A1 (en) | ANTIMICROBIAL AGENTS | |
DE10008894A1 (en) | Cosmetic and dermatological light protection formulations containing unsymmetrically substituted triazine derivatives and alkyl naphthalates | |
DE3038963C2 (en) | ||
DE3202613A1 (en) | ANTIMYCOTIC AGENTS | |
FR2801586A1 (en) | PHOTOPROTECTIVE COSMETIC COMPOSITIONS CONTAINING AMINOAMIDINE DERIVATIVES AND USES THEREOF | |
US10426744B2 (en) | Anti-fungal compositions for treating nails and methods for fabricating and using thereof | |
CA2533720A1 (en) | Antimycosic nail varnish | |
EP1048288B1 (en) | Use of halogenated antimycotic- and cationic antibacterial-compounds for the treatment of dandruff | |
RU2203280C2 (en) | Derivatives of triazole eliciting antifungal activity | |
WO2013107809A1 (en) | Use of azole antifungals for the treatment of actinic keratosis | |
EP0315861A1 (en) | Antimycotic compositions of a nikkomycin compound and an antimycotic azole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17P | Request for examination filed |
Effective date: 20021220 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: FLADUNG, BERNWARD Inventor name: DR.PETERSEN-BRAUN, MARIANNE Inventor name: ENZMANN, HARALD |
|
17Q | First examination report despatched |
Effective date: 20030428 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER HEALTHCARE AG |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RTI1 | Title (correction) |
Free format text: USE OF AZOLES FOR PREVENTING SKIN CANCER DUE TO RADIATION |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20050831 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
REF | Corresponds to: |
Ref document number: 50011084 Country of ref document: DE Date of ref document: 20051006 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20050402829 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20051115 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20051116 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20051118 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20051123 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20051124 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20051206 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20051207 Year of fee payment: 6 Ref country code: FI Payment date: 20051207 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20051209 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20051212 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20051215 Year of fee payment: 6 Ref country code: MC Payment date: 20051215 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20051228 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20051230 Year of fee payment: 6 |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20051214 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2246912 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20060601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061212 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061212 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061213 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20061213 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20061228 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061231 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061231 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20061231 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20070103 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070612 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20070612 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070703 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed | ||
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20070831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061212 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061212 |
|
BERE | Be: lapsed |
Owner name: *BAYER HEALTHCARE A.G. Effective date: 20061231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070102 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20061213 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061213 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070102 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20071212 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20080701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070704 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071212 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071212 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071212 |